Profund Advisors LLC Buys 656 Shares of DexCom, Inc. (NASDAQ:DXCM)

Profund Advisors LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 1.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,972 shares of the medical device company’s stock after purchasing an additional 656 shares during the period. Profund Advisors LLC’s holdings in DexCom were worth $3,965,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new stake in shares of DexCom during the 1st quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom in the second quarter valued at about $25,000. DSM Capital Partners LLC bought a new position in DexCom in the fourth quarter valued at about $28,000. Riverview Trust Co acquired a new stake in shares of DexCom during the first quarter valued at about $32,000. Finally, Sachetta LLC grew its holdings in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 2.1 %

DexCom stock opened at $70.43 on Friday. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $28.01 billion, a PE ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18. The firm’s fifty day moving average is $78.19 and its 200 day moving average is $109.54. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the sale, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,483 shares of company stock valued at $201,708. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on DXCM shares. Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Robert W. Baird increased their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Wells Fargo & Company cut their target price on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 26th. Finally, UBS Group decreased their price target on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.